A single injection of gene therapy has restored hearing in all ten patients with congenital deafness, marking a significant advance in treating genetic hearing loss.
The treatment worked across ages from toddlers to adults, with some patients recovering nearly normal hearing within months. Published in Nature Medicine, the study demonstrates that gene therapy can rapidly repair the molecular machinery needed for sound transmission from ear to brain.
The patients, aged 1.5 to 24 years, all had mutations in the OTOF gene that prevented production of otoferlin—a protein essential for transmitting auditory signals. Using a modified virus to deliver a functional copy of the gene directly into the inner ear, researchers achieved dramatic hearing improvements that began within weeks.
Rapid Recovery Across Age Groups
The results exceeded expectations in both speed and scope. “This is a huge step forward in the genetic treatment of deafness, one that can be life-changing for children and adults,” explains Maoli Duan, consultant and docent at Karolinska Institutet and one of the study’s corresponding authors.
The therapy’s effects appeared remarkably quickly, with most patients showing hearing improvement within just one month. On average, patients’ hearing thresholds improved from 106 decibels—equivalent to profound deafness—to 52 decibels, bringing many into ranges where conversation becomes possible.
One seven-year-old girl achieved the most dramatic recovery, regaining almost all her hearing and holding daily conversations with her mother just four months after treatment. The study also proved that gene therapy could work in teenagers and adults—populations never before tested with this approach.
Key Treatment Outcomes
The multicenter trial across five Chinese hospitals revealed several important findings:
- All ten patients experienced significant hearing improvement within six months
- 62% of total hearing recovery occurred within the first month of treatment
- Children aged 5-8 years showed optimal responses to therapy
- No serious adverse reactions occurred during the 6-12 month follow-up period
- One patient safely received two injections, opening possibilities for booster treatments
Precision Medicine at the Molecular Level
The treatment targets autosomal recessive deafness 9 (DFNB9), caused by mutations that disrupt otoferlin production. This protein acts like molecular velcro, helping sound-detecting hair cells release neurotransmitters that carry auditory signals to the brain. Without functional otoferlin, patients can have intact hair cells but cannot transmit sound information.
Researchers used a synthetic adeno-associated virus called Anc80L65 to deliver the therapeutic gene through a single injection into the cochlea via the round window membrane. The procedure, performed under microscopic guidance, takes advantage of the virus’s natural ability to infect inner ear cells and deposit genetic material.
The international collaboration involved researchers from China working with experts at Karolinska Institutet. “Smaller studies in China have previously shown positive results in children, but this is the first time that the method has been tested in teenagers and adults, too,” notes Dr. Duan.
Age-Dependent Responses Reveal Optimal Window
Perhaps most intriguingly, the study uncovered an age-dependent pattern in treatment effectiveness. While all patients improved, those between 5-8 years old achieved the best outcomes—better than both younger toddlers and older participants.
This finding challenges assumptions that younger patients should always respond better to gene therapy. The researchers speculate that factors like surgical precision, inner ear development, or viral transduction efficiency may vary with age, though the exact mechanisms remain unclear.
The treatment proved safe across all ages, with the most common side effect being temporarily reduced white blood cell counts. No serious adverse reactions occurred, even in a patient who received a second injection when initial results were modest.
Looking ahead, researchers plan to expand their work to other genetic causes of deafness. “OTOF is just the beginning,” says Dr. Duan. “We and other researchers are expanding our work to other, more common genes that cause deafness, such as GJB2 and TMC1.”
With an estimated 1.5 billion people worldwide experiencing hearing loss, genetic approaches like this offer hope for treating conditions once considered permanently irreversible. The rapid recovery timeline—with most benefits appearing within the first month—suggests that gene therapy could become a practical clinical option for appropriately selected patients with genetic hearing loss.
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.